Integra LifeSciences posts Q1 revenue of $391.9m amid leadership change
Integra LifeSciences has reported first-quarter 2026 revenues of $391.9 million, a 2.4% increase on a reported basis and 1.3% on an organic basis year-on-year, as the Princeton, New Jersey-based medical technology company pressed ahead with a manufacturing and operational overhaul that began following a product recall in 2023.
The company posted a GAAP net loss of $4.6 million, or $0.06 per diluted share, narrowing sharply from a loss of $25.3 million, or $0.33 per diluted share, in the same period a year earlier. On an adjusted basis, earnings per diluted share came in at $0.54, up from $0.41 in Q1 2025, while adjusted EBITDA improved to $76.2 million — representing 19.4% of revenue — against $63.6 million, or 16.6% of revenue, in the prior year.
Segment performance and manufacturing progress
Integra's two reporting segments — Specialty Surgery (formerly Codman Specialty Surgical) and Tissue Reconstruction (formerly Tissue Technologies) — delivered contrasting performances. Specialty Surgery, which accounts for roughly 70% of group revenues, recorded total revenues of $283.1 million, representing organic growth of just 0.6% against the prior year. Within the segment, neurosurgery products — including Certas Plus, CUSA, and Bactiseal — grew 1.9% organically, while the instruments sub-category fell 7.7% on order timing, and ENT revenues declined 3.8%.
Tissue Reconstruction, at approximately 30% of revenues, was the stronger performer with revenues of $108.8 million, up 6.7% reported and 6.4% organically. The unit was driven by double-digit growth in Integra Skin and the relaunch of PriMatrix, a dermal regeneration template, alongside DuraSorb. The company noted meaningful progress at its Braintree, Massachusetts manufacturing facility, which is replacing capacity lost following the Boston site recall, and said it remains on track to begin SurgiMend production there by end of June, targeting a fourth-quarter commercial launch.
Stuart Essig, who was simultaneously confirmed as the incoming President and Chief Executive Officer in a separate announcement on the same day, said the results reflected "solid product demand and the continued impact of our transformation efforts," adding that "operational rigour and improved execution" were beginning to take hold across the organisation. Michael McBreen was promoted to Chief Commercial Officer as part of the leadership restructuring.
Market context and guidance
Integra carries net debt of $1.6 billion and a consolidated leverage ratio of 4.1x, which leaves limited financial flexibility relative to peers in the broad medical technology sector. The company generated $9.8 million in operating cash flow in the quarter, a significant reversal from the $11.3 million outflow recorded in Q1 2025, though free cash flow remained negative at $(5.0) million due to capital expenditure. Total liquidity stood at approximately $488 million as of 31 March.
For the full year 2026, Integra reiterated its revenue guidance range of $1.662 billion to $1.702 billion — representing organic growth of 0.8% to 3.3% — and lifted its adjusted EPS guidance to $2.40–$2.50, up from the prior range of $2.30–$2.40. The company noted the upgraded EPS range partly reflects benefits associated with IEEPA tariff provisions. For Q2, it guided revenues of $410 million to $425 million and adjusted EPS of $0.44 to $0.52.
The medical technology sector broadly is navigating supply chain headwinds and elevated capital costs, with neurosurgery and wound care device makers facing sustained pressure on reimbursement rates in major markets. Integra's near-term investment case is closely tied to the Braintree facility reaching full operational capacity, restoring product lines that were disrupted by the 2023 recall. Investors will be watching Q3 and Q4 supply metrics as the clearest signal of whether the company's transformation programme is delivering durable recovery.